Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Outlook Therapeutics (OTLK) over the last 8 years, with Q4 2025 value amounting to $30074.0.

  • Outlook Therapeutics' Depreciation & Amortization (CF) rose 442.0% to $30074.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $118325.0, marking a year-over-year decrease of 6289.31%. This contributed to the annual value of $117052.0 for FY2025, which is 280.43% up from last year.
  • Outlook Therapeutics' Depreciation & Amortization (CF) amounted to $30074.0 in Q4 2025, which was up 442.0% from $29737.0 recorded in Q3 2025.
  • Over the past 5 years, Outlook Therapeutics' Depreciation & Amortization (CF) peaked at $30074.0 during Q4 2025, and registered a low of $28801.0 during Q4 2024.